Pharvaris (PHVS) Profit After Tax (2020 - 2026)
Pharvaris (PHVS) reported Profit After Tax of -$45.9 million for Q1 2026, up 5.85% on a YoY basis from -$43.4 million in Q1 2025, and up 15.65% quarter-over-quarter from -$54.4 million in Q4 2025.
Pharvaris (PHVS) Profit After Tax (2020 - 2026) Analysis & Trends
Pharvaris has reported Profit After Tax for 7 years, with the latest figure at -$45.9 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax rose 5.85% year-over-year to -$45.9 million; the trailing twelve-month figure through Mar 2026 stood at -$195.2 million (down 19.23% YoY), and the FY2025 full-year result was -$198.5 million, down 36.64% from the prior year.
- Profit After Tax for Q1 2026 stood at -$45.9 million, up from -$54.4 million in the prior quarter.
- The five-year high for Profit After Tax was -$8.6 million in Q3 2022, with the low at -$54.4 million in Q4 2025.
- Historically, Profit After Tax has averaged -$34.0 million across 5 years, with a median of -$35.2 million in 2023.
- Annual changes were most pronounced in 2022 — Profit After Tax increased 26.44% — and 2023, when it plunged 200.18%.
- Pharvaris' Profit After Tax stood at -$40.0 million in 2022, then rose by 11.89% to -$35.2 million in 2023, then declined by 5.42% to -$37.1 million in 2024, then tumbled by 46.47% to -$54.4 million in 2025, then rose by 15.65% to -$45.9 million in 2026.
- The last three Profit After Tax figures came in at -$45.9 million (Q1 2026), -$54.4 million (Q4 2025), and -$43.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.74 Mn |
| 10 | Pharvaris | 28.66 Bn | 28.37 Bn | - | -45.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.89 Mn |
| Dec 31, 2025 | -54.41 Mn |
| Sep 30, 2025 | -43.42 Mn |
| Jun 30, 2025 | -51.48 Mn |
| Mar 31, 2025 | -48.75 Mn |
| Dec 31, 2024 | -37.15 Mn |
| Sep 30, 2024 | -45.81 Mn |
| Jun 30, 2024 | -32.02 Mn |
| Mar 31, 2024 | -30.44 Mn |
| Dec 31, 2023 | -35.23 Mn |
| Sep 30, 2023 | -25.69 Mn |
| Jun 30, 2023 | -23.85 Mn |
| Mar 31, 2023 | -24.29 Mn |
| Dec 31, 2022 | -39.99 Mn |
| Sep 30, 2022 | -8.56 Mn |
| Jun 30, 2022 | -13.47 Mn |
| Mar 31, 2022 | -17.99 Mn |
| Dec 31, 2021 | -14.12 Mn |
| Sep 30, 2021 | -10.78 Mn |
| Jun 30, 2021 | -18.31 Mn |